Biosimilars Mvasi and Kanjinti are now available in the United States.
The sNDA is supported by data from the multicenter phase 2 QUADRA trial that evaluated the safety and activity of Zejula in 463 patients.
Pointers for nurses on PARP inhibitors, including indications, adverse effects, and points for counseling patients.
A new study challenges the recommended use of cotesting for cervical cancer screening.
[Cancer Management and Research] A meta-analysis of randomized controlled trials sought to confirm the effectiveness and safety of olaparib for the treatment of relapsed BRCA-mutated ovarian cancer.